Jiangsu Hengrui Pharmaceuticals, a Chinese developer of novel drugs, could receive up to US$1.01 billion in milestone payments after granting a US company exclusive rights to develop a heart disease drug, the latest example of mainland drug makers licensing early-stage assets to international partners. Jiangsu Hengrui entered into a licensing agreement with one-year-old US start-up Braveheart Bio for its innovative drug HRS-1893 to treat obstructive hypertrophic cardiomyopathy, according to a...